Ocugen, Inc. 8-K

What Happened

• Ocugen, Inc. announced via press release (filed as Exhibit 99.1) that it closed an underwritten offering of 15,000,000 shares of common stock at $1.50 per share. The offering closed on January 22, 2026; the press release was issued January 23, 2026.
• The gross proceeds from the sale equal approximately $22.5 million. The company states it anticipates these proceeds will extend its cash runway into the fourth quarter of 2026.

Key Details

• Offering size: 15,000,000 shares at $1.50 per share (gross proceeds ≈ $22.5M).
• Closing date: January 22, 2026; press release announcing closing dated January 23, 2026.
• Company guidance: proceeds expected to fund operations into Q4 2026.
• Filing: Form 8-K includes Regulation FD disclosure and a forward‑looking statements caution noting risks that could change outcomes.

Why It Matters

• The transaction provides near-term funding, which the company says should support operations into late 2026. For investors, that reduces near-term financing pressure.
• The offering is dilutive: 15 million new shares were issued, increasing share count and potentially affecting per‑share metrics and market supply.
• The company’s forward‑looking statement warns that actual results may differ due to market conditions and other risks disclosed in Ocugen’s SEC filings.